^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BCG vaccine

i
Other names: BCG vaccine
Associations
Trials
Company:
University of Campinas
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
8ms
IMMUNOBCG: Immunological Response of Bladder Cancer Patients Under BCG (clinicaltrials.gov)
P3, N=30, Suspended, University of Campinas, Brazil | Trial completion date: Nov 2023 --> Dec 2028 | Completed --> Suspended | Trial primary completion date: May 2022 --> Dec 2026
Trial completion date • Trial suspension • Trial primary completion date
|
BCG vaccine
12ms
IMMUNOBCG: Immunological Response of Bladder Cancer Patients Under BCG (clinicaltrials.gov)
P3, N=30, Completed, University of Campinas, Brazil | Active, not recruiting --> Completed
Trial completion
|
BCG vaccine
2years
Castration immunoregulates toll-like receptor-4 in male bladder cancer. (PubMed, Int Urol Nephrol)
To our knowledge, this is the first description of TLR-4 urothelial expression hormonal modulation. The described castration-mediated immunomodulation will help to improve the knowledge of urothelial cancer gender diversities and PRRs modulations with treatment implications.
Journal • IO biomarker
|
TLR4 (Toll Like Receptor 4)
|
BCG vaccine
over2years
Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model. (PubMed, Med Oncol)
After treatment with MNU, the rats were distributed into four experimental groups: Control (without MNU) group, MNU (cancer) group, MNU-BCG (Bacillus Calmette-Guerin) group, and MNU-P-MAPA group...These alterations were fundamental for histopathological recovery from cancer and for suppress abnormal cell proliferation. This action of P-MAPA on apoptotic pathways may represent a new strategy for treating NMIBC.
Preclinical • Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
TP53 wild-type
|
BCG vaccine
over2years
OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway. (PubMed, Tissue Cell)
The new modalities for treating patients with high-grade non-muscle invasive bladder cancer (HGNMIBC) for whom Bacillus Calmette-Guerin (BCG) has failed or is contraindicated are recently increasing due to the development of new drugs...Immunohistochemical analysis demonstrated that while the conventional BCG treatment stimulated the canonic pathway, OncoTherad® (MRB-CFI-1) stimulated the non-canonical pathway (increasing expression of TLR4, TRIF, IRF, and IFNγ). OncoTherad® (MRB-CFI-1) could be considered a promising therapy in the treatment of NMIBC.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
BCG vaccine